ELTP
ELITE PHARMS INC
stockOTC
elite pharmaceuticals, inc. develops oral sustained and controlled release products. elite's strategy includes assisting partner companies in the life cycle management of products, to improve off-patent drug products, and developing generic versions of controlled release drug products with high barriers to entry. elite has four anda products partnered with tagi pharma; one anda has launched, two andas are in the process of a manufacturing site transfer and an additional anda is currently under review by the fda. elite also manufactures lodrane d® and receives royalties for lodrane d®, an allergy product partnered with ecr pharmaceuticals ("ecr"), a wholly owned subsidiary of hi-tech pharmacal ("hi-tech"). elite's lead pipeline products, eli-216, a once-daily abuse resistant oxycodone, and eli-154, a once-daily oxycodone, are novel sustained release oral formulations of opioids for the treatment of chronic pain, which address two of the limitations of existing oral opioids: the provisio
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 0.25 | 2026-09-28 | -9.05% | 2.261 |
| 1M | 0.26 | 2026-09-04 | -11.38% | 1.481 |
| 3M | 0.36 | 2026-07-06 | -36.49% | 0.304 |
| 6M | 0.38 | 2026-04-06 | -39.08% | 0.151 |
| 1Y | 0.64 | 2025-10-03 | -64.27% | 0.659 |
| 2Y | 0.39 | 2024-10-04 | -41.63% | — |
| 5Y | 0.04 | 2021-10-04 | +450.96% | 0.225 |
ELITE PHARMS INC (OTC:ELTP) stock price today is $0.23, and today's volume is 1,868,124. ELTP is up 0.727% today. The 30 day average volume is 847,018. ELTP market cap is $244.26M with 1.07B shares outstanding.